What Viz.ai’s latest hypertrophic cardiomyopathy studies reveal about the future of cardiac AI
Viz.ai’s new HCM studies suggest AI-ECG could improve detection and follow-up. Read what this changes for cardiology workflows and adoption.
Why Roche’s Phase III bet on prasinezumab is bigger than its Phase IIb result suggests
Roche and BMS present updated prasinezumab and BMS-986446 data at AD/PD 2026. What it means for Phase III plans and tau targeting. Read the analysis.
How Bristol Myers Squibb’s Opdivo approvals in frontline and relapsed classical Hodgkin lymphoma reset treatment pathways
Nivolumab wins U.S. frontline and EU relapsed cHL approvals. Analyse what the dual verdict means for sequencing, safety, and reimbursement.
Bristol Myers Squibb expands Sotyktu label. Will TYK2 inhibition challenge biologics in psoriatic arthritis?
FDA approves Bristol Myers Squibb’s Sotyktu for psoriatic arthritis. Discover what TYK2 inhibition means for autoimmune treatment and future rheumatology drugs.
What Bristol Myers Squibb’s luspatercept results reveal about the future of alpha thalassemia care
Bristol Myers Squibb reports positive luspatercept data in alpha thalassemia. Find out what this could change for treatment and regulation.
Bristol Myers Squibb pushes CELMoD frontier as FDA accepts iberdomide NDA in relapsed multiple myeloma
FDA accepts Bristol Myers Squibb’s iberdomide NDA for relapsed multiple myeloma. Find out what this CELMoD filing could change next.
NMPA clears Zai Lab’s COBENFY, rewriting the schizophrenia treatment playbook
Zai Lab’s COBENFY approved in China as a first-in-class schizophrenia treatment. Find out what this milestone means for psychiatry and pharma innovation.
Can Harbour BioMed’s deal with Bristol Myers Squibb redefine the future of multispecific antibodies?
Harbour BioMed has signed a global strategic collaboration and license agreement with Bristol Myers Squibb to discover and develop next-generation multispecific antibodies. The deal could be worth over $1.1 billion across upfront payments, milestones, and royalties. It also signals growing interest in platforms capable of generating novel immunotherapies for complex diseases. The announcement is not […]
Can nivolumab plus AVD become the new frontline treatment in classical Hodgkin lymphoma?
FDA fast-tracks review of Opdivo plus AVD for first-line Hodgkin lymphoma. Find out what this immunotherapy combo could change for patients and providers.